ARIA risks and MRI monitoring

A new Health Canada-approved drug called lecanemab has been shown to slow early-stage Alzheimer's disease. Neurologist Dr. Sharon Cohen, who participated in phase three trials for the drug, explains why lecanemab is such a big deal.

For transcripts of The Dose, please visit: lnk.to/dose-transcripts. Transcripts of each episode will be made available by the next workday. For more episodes of this podcast, click this link.